Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 10—October 2026

Research

Multisectoral Emergence of Multidrug-Resistant Campylobacter coli Sequence Type 10042 Lineage, Europe, 2018–2025

Mónica Azevedo1, Alexandra Nunes1, Maria-Leonor Lemos, Paulo Martins Costa, Ana Amaro, Lurdes Clemente, Célia Leão, Sónia Ramos, Isabel Santos, Katrine Grimstrup Joensen, Catherine Ragimbeau, Lena de Baets, Joël Mossong, Sangeeta Banerji, Antje Flieger, Diana Espadinha, William Byrne, Oda van den Berg, Andries Augustus Kampfraath, Quentin Jehanne, Philippe Lehours, João Paulo Gomes, and Mónica OleastroComments to Author 
Author affiliation: National Institute of Health Doutor Ricardo Jorge (INSA), Lisbon, Portugal (M. Azevedo, A. Nunes, M.-L. Lemos, J.P. Gomes); Research in Veterinary Medicine (I-MVET)/Animal and Veterinary Research Center (CECAV), Faculty of Veterinary Medicine, Lusófona University—Lisbon University Centre, Lisbon (A. Nunes, S. Ramos, I. Santos, J.P. Gomes); ICBAS-Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal (M.-L. Lemos, P.M. Costa); Laboratory of Bacteriology and Mycology, National Institute of Agrarian and Veterinary Research, Oeiras, Portugal (A. Amaro, L. Clemente, C. Leão); Statens Serum Institut, Copenhagen, Denmark (K.G. Joensen); Laboratoire National de Santé, Dudelange, Luxembourg (C. Ragimbeau); Laboratoire Vétérinaire et Alimentaire, Division of the Luxembourg Veterinary and Food Administration, Dudelange (L. de Baets); Ministère de la Santé et de la Sécurité Sociale, Direction de la Santé, Luxembourg, Luxembourg (J. Mossong); Robert Koch-Institute, Wernigerode, Germany (S. Banerji, A. Flieger); Public Health Laboratory Dublin, Health Service Executive, Dublin, Ireland (D. Espadinha); Backweston Complex, Celbridge, Ireland (W. Byrne); National Institute of Public Health and the Environment (RIVM), Bilthoven, the Netherlands (O. van den Berg); European Centre for Disease Prevention and Control, Stockholm, Sweden (O. van den Berg); Wageningen Bioveterinary Research, Wageningen UR, Lelystad, the Netherlands (A.A. Kampfraath); French National Reference Centre for Campylobacters and Helicobacters, Bordeaux Hospital University Centre, Bordeaux, France (Q. Jehanne, P. Lehours); University of Bordeaux, INSERM, Bordeaux Institute of Oncology, Bordeaux (P. Lehours)

Main Article

Table 3

Campylobacter coli ST10042 isolates phenotypic and genotypic (antimicrobial resistance profiles in study of multisectoral emergence of multidrug-resistant C. coli ST10042 lineage, Europe, 2018–2025*

Class Antibiotic Phenotype, n = 98, NRL-GI Portugal isolates
 Genotype, N = 217, all isolates
Disk, mm, or MIC, mg/L Susceptibility No. tested/ no. positive Resistance determinants No. tested/ no. positive
Fluoroquinolones
 Ciprofloxacin
 6 mm
 R
 98/98
GyrA Thr86Ile
 217/217
Tetracyclines
 Tetracycline
 6 mm
 R
 98/98
tet(32/O/32) 213/217
tet(O)
 4/217
β-lactams Ampicillin >256 mg/L R 98/98 blaOXA-61 216/217
blaOXA-61 promoter: −57G>T
Amoxicillin/clavulanic acid >256 mg/L R 1/98 blaOXA-61 1/217
blaOXA-61 promoter: −57G>T
−69delA
porA 35
12–64 mg/L R 95/98 blaOXA-61 211/217
blaOXA-61 promoter: −57G>T
porA 35/1006/4736
8/0.094 mg/L S 2/98 blaOXA-61 4/217
blaOXA-61 promoter: −57G>T
– blaOXA-61 1/217
porA 35
Carbapenems
 Ertapenem
 0.30–1.0 mg/L DS 96/98 porA 35/1006/4736† 213/217
0.032/0.125 mg/L
 S
 2/98
x
 4/217
Macrolides Erythromycin 6 mm/>256 mg/L R 2/98 23S rRNA (A2075G) 6/217
23S rRNA (A2074G) 1/217
23S rRNA (A2074C) 1/217
>24 mm S 96/98 x 209/217

*Dash indicates no antimicrobial susceptibility testing was performed. X indicates absence of resistance determinants. DS, decreased susceptibility; NRL-GI, National Reference Laboratory for Gastrointestinal Infections; R, resistant; S, susceptible; ST, sequence type. †porA 1006 and porA 4736 differ from allele 35 by a single synonymous substitution. Other genetic determinants included: aadE (n = 1/217), aad9 (n = 1/217), aph(3′)-IIIa (n = 1/217) and ant (6)-Ia (n = 3/217). Gentamicin was tested and found to be susceptible for NRL-GI Portuguese isolates (>17 mm). Zone diameter breakpoints for ciprofloxacin (S >26 mm), tetracycline (S >30) and erythromycin (S >24 mm), and MIC breakpoint for erythromycin (S <8 mg/L) established by EUCAST v16.1 were used; interpretive criteria for ampicillin (S <8 mg/L), amoxicillin/clavulanic acid (S <8 mg/L) and ertapenem (S <1 mg/L), established by the CA-SFM V.1.1 were used.

Main Article

1These authors contributed equally to this work and share first authorship.

Page created: August 13, 2026
Page updated: September 18, 2026
Page reviewed: September 18, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external